A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro.

Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, USA.
International Journal of Antimicrobial Agents (Impact Factor: 4.42). 05/2008; 31(4):369-74. DOI:10.1016/j.ijantimicag.2007.11.015
Source: PubMed

ABSTRACT We developed a pharmacokinetic/pharmacodynamic (PK/PD) mathematical model that fits voriconazole time-kill data against Candida isolates in vitro and used the model to simulate the expected kill curves for typical intravenous and oral dosing regimens. A series of Emax mathematical models were used to fit time-kill data for two isolates each of Candida albicans, Candida glabrata and Candida parapsilosis. PK parameters extracted from human data sets were used in the model to simulate kill curves for each isolate. Time-kill data were best fit by using an adapted sigmoidal Emax model that corrected for delays in candidal growth and the onset of voriconazole activity, saturation of the number of Candida and the steepness of the concentration-response curve. The rates of maximal killing by voriconazole (kmax) were highly correlated with the growth rates (ks) of the isolates (Pearson's correlation coefficient=0.9861). Simulations using PK parameters derived from the human data sets showed fungistatic effects against each of the isolates. In conclusion, we demonstrated that the activity of voriconazole against Candida isolates can be accurately described using a mathematical model. In the future, it might be possible to devise optimal dosing regimens of voriconazole using the model and PK data collected in vivo.

0 0
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: The pharmacodynamics (PD) of voriconazole activity against Aspergillus spp. were studied using a new in vitro dynamic model simulating voriconazole human pharmacokinetics (PK), and the PK-PD data were bridged with human drug exposure to assess the percent target (near-maximum activity) attainment of different voriconazole dosages. Three Aspergillus clinical isolates (1 A. fumigatus, 1 A. flavus, and 1 A. terreus isolate) with CLSI MICs of 0.5 mg/liter were tested in an in vitro model simulating voriconazole PK in human plasma with C(max) values of 7, 3.5, and 1.75 mg/liter and a t(1/2) of 6 h. The area under the galactomannan index-time curve (AUC(GI)) was used as the PD parameter. In vitro PK-PD data were bridged with population human PK of voriconazole exposure, and the percent target attainment was calculated. The in vitro PK-PD relationship of fAUC(0-24)-AUC(GI) followed a sigmoid pattern (global R(2) = 0.97), with near-maximum activities (10% fungal growth) observed at an fAUC(0-24) (95% confidence interval [CI]) of 18.9 (14.4 to 23.1) mg · h/liter against A. fumigatus, 26.6 (21.1 to 32.9) mg · h/liter against A. flavus, and 36.2 (27.8 to 45.7) mg · h/liter against A. terreus (F test; P < 0.0001). Target attainment for 3, 4, and 5 mg/kg-of-body-weight voriconazole dosages was 24% (11 to 45%), 80% (32 to 97%), and 93% (86 to 97%) for A. fumigatus, 12% (5 to 26%), 63% (17 to 93%), and 86% (73 to 94%) for A. flavus, and 4% (2 to 11%), 36% (6 to 83%), and 68% (47 to 83%) for A. terreus. Based on the in vitro exposure-effect relationships, a standard dosage of voriconazole may be adequate for most patients with A. fumigatus but not A. flavus and A. terreus infections, for which a higher drug exposure may be required. This could be achieved using a higher voriconazole dosage, thus highlighting the usefulness of therapeutic drug monitoring in patients receiving a standard dosage.
    Antimicrobial Agents and Chemotherapy 08/2012; 56(10):5321-7. · 4.57 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Clinical practice guidelines recommend performing follow-up cultures for patients with candidemia in order to determine the time when Candida is cleared from the bloodstream. Since this requires collecting blood cultures from patients undergoing antifungal treatment, we evaluated two blood culture bottles (Bactec™ Mycosis IC/F (MICF), specifically adapted to the growth of fungi, and Bactec™ Plus Aerobic/F (PAF) containing resins to inactivate anti-infective agents) as to their effectiveness to detect C. albicans and C. glabrata when seeded in concentrations of 1 cfu/ml and 10 cfu/ml, respectively, together with human whole blood and different antifungal agents in therapeutic peak serum concentrations (Cmax). Significant differences between MICF and PAF vials for the detection of Candida spp. were found when inoculated with caspofungin (0/12 vs. 8/12; p<0.001) and amphotericin B (3/12 vs. 12/12; p<0.001). Inoculation of both fluconazole and voriconazole did not influence the effectiveness of detection in both MICF and PAF bottles (p=1.0). Neither MICF nor PAF bottles detected Candida spp. reliably when seeded together with anidulafungin (1/12 vs. 1/12; p=1.0) or micafungin (0/12 vs. 1/12; p=1.0). The time-to-positivity of both bottles when antifungal agents were added was significantly prolonged compared to controls without antimycotic drugs (p<0.001). Overall, the results of this in vitro study indicate that PAF bottles detected Candida spp. more reliably compared with MICF bottles when supplemented with certain antifungal agents. In consequence, clinical studies should now evaluate whether this holds true when taking blood cultures from patients undergoing antifungal treatment.
    Journal of clinical microbiology 08/2013; · 4.16 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: A mathematical pharmacodynamic model was developed to describe the bactericidal activity of marbofloxacin against Escherichia coli strains with reduced susceptibility levels (determined using MICs) under optimal and intestinal growth conditions. Model parameters were estimated using nonlinear least-square curve-fitting procedures for each E. coli strain. Parameters related to bactericidal activity were subsequently analyzed using a maximum-effect (E(max)) model adapted to account for a direct and a delayed effect. While net growth rates did not vary significantly with strain susceptibility, culture medium had a major effect. The bactericidal activity of marbofloxacin was closely associated with the concentration and the duration of exposure of the bacteria to the antimicrobial agent. The value of the concentration inducing a half-maximum effect (C(50)) was highly correlated with MIC values (R(2) = 0.87 and R(2) = 0.94 under intestinal and optimal conditions, respectively). Our model reproduced the time-kill kinetics with good accuracy (R(2) of >0.90) and helped explain observed regrowth.
    Antimicrobial Agents and Chemotherapy 11/2010; 55(2):756-61. · 4.57 Impact Factor

Full-text (2 Sources)

Available from
Aug 12, 2013